Subscribe to RSS
DOI: 10.1055/s-0031-1296232
Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers
Publication History
Publication Date:
03 December 2011 (online)
![](https://www.thieme-connect.de/media/amf/201109/lookinside/thumbnails/10.1055-s-0031-1296232-1.jpg)
Abstract
One bioequivalence study was carried out in healthy volunteers in order to compare the rate and extent of absorption of two oral formulations of quetiapine fumarate (CAS 111974-72-2) 25 mg film-coated tablet. Thirty subjects were administered quetiapine fumarate film-coated tablet of test and reference formulation in an open-label, randomised, fasting, two-period, two-sequence, crossover study. Blood samples were taken before and within 48 h after drug administration. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUC and Cmax values were tested for bioequivalence based on the ratios of the geometric means (test/reference). Tmax was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC0–t and Cmax were within the bioequivalence acceptance range of 80– 125%. It may be therefore concluded that the test formulation of quetiapine fumarate 25 mg film-coated tablet is bioequivalent to the reference product and can be prescribed interchangeably.
-
References
- 1 Seroquel® label information [Internet]. Food and Drug Administration; [cited 2010 Nov 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020639s045s046lbl.pdf
- 2 CPMP (Committee for Proprietary Medicinal Prodcuts) Guideline on the Investigation of Bioequivalence. London: 2010
- 3 Thyrum P, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuro-Psychopharmacol Biol Psychiat. 2000; 24: 521-33
- 4 Good Clinical Practice Consolidated Guideline, International Conference on Harmonisation, E6. 1996.
- 5 Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvantis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone or thioridazine. J Clin Psychopharmacol. 2002; 22: 121-30
- 6 Chow SC, Liu JP. Power and sample size determination. In: Chow SC, Liu JP. editors Design and analysis of bioavailability and bioequivalence studies. 2nd ed. New York: Marcel Dekker; 2000: 125-160
- 7 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-80
- 8 Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-8
- 9 Wijnand HP. Updates of bioequivalence programs (including statistical power approximation by Student’s t). Corn-put Method Programs Biomed. 1994; 42: 275-81
- 10 Seroquel® Summary of Product Characteristics [Internet]. Spanish Medicines and Healthcare Products Agency; [cited 2010 Nov 17]. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=63054&formato=pdf&formulario=FICHAS